24th Oct 2016 08:13
LONDON (Alliance News) - Sareum Holdings PLC said Monday it has filed a patent application for intellectual property from a successful feasibility study for its leukemia treatment programme.
AIM-listed Sareum, a cancer drug development company, said the feasibility study into its TYK2 inhibitor had shown positive results in tumour reduction when treating T-cell acute lymphoblastic leukemia, along with good toleration to an oral dosage.
Sareum said it has now filed a patent application to protect the new intellectual property arising from the research.
The study was part-funded by a GBP140,000 award from government agency Innovate UK.
"We are delighted with the outcome of this study. It has successfully demonstrated the potential of our TYK2 inhibitors to treat this leukaemia. We believe commercial interest in this programme should increase further as a result, and we are grateful to Innovate UK for their financial support. The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," said John Reader, chief scientific officer of Sareum.
Shares in Sareum were broadly flat at 1.10 pence early Monday.
By Adam Clark; [email protected]
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Sareum